In this study, SLC1A5 inhibition not only enhanced the anti-tumor effect of Almonertinib on EGFR mutant cell lines (H1975), but greatly improved the anti-tumor effect of Almonertinib on EGFR WT cell lines (A549). This evidence concerns the gene SLC1A5 and neoplasm.